Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience
Étienne Crickx, Mikaël Ebbo, Étienne Rivière, O. Souchaud-Debouverie, Louis Terriou, Sylvain Audia, M. Ruivard, Bouchra Asli, Jean‐Pierre Marolleau, N. Méaux-Ruault, Mathieu Gerfaud‐Valentin, Philippe Audeguy, M. Hamidou, Sélim Corm, X. Delbrel, Jean Fontan, Delphine Lebon, C. Mausservey, Guillaume Moulis, Nicolas Limal, Marc Michel, Bertrand Godeau, Matthieu Mahévas
Abstract
Summary Combining drugs could be an effective option for treating multirefractory ITP, that is, patients not responding to rituximab, thrombopoietin receptor agonists (TPO‐RA) and splenectomy. We conducted a retrospective, multicenter, observational study including multirefractory ITP patients who received a combination of a TPO‐RA and an immunosuppressive drug. We included 39 patients (67% women, median age 59 years [range 21–96]), with a median ITP duration of 57 months [3–393] and a median platelet count at initiation of 10 × 10 9 /L [1–35]. The combination regimen was given for a median duration of 12 months [1–103] and included eltrombopag (51%) or romiplostim (49%), associated with mycophenolate mofetil (54%), azathioprine (36%), cyclophosphamide (5%), cyclosporin (3%) or everolimus (3%). Overall, 30 patients (77%) achieved at least a response (platelet count ≥30 × 10 9 /L and at least doubling baseline during at least 3 months), including 24 complete responses (platelet count >100 × 10 9 /L during at least 3 months) with a median time to response of 30 days [7–270] and a median duration of response of 15 months [4–63]. Severe adverse event related to ITP treatment was observed in 31%. In conclusion, this study confirms that some patients with multirefractory ITP can achieve long lasting response with this combination.